Zobrazeno 1 - 10
of 44
pro vyhledávání: '"C. Cailliot"'
Autor:
P. Gougis, M. Carton, C. Tchokothe, M. Campone, F. Dalenc, A. Mailliez, C. Levy, W. Jacot, M. Debled, M. Leheurteur, T. Bachelot, A. Hennequin, C. Perrin, A. Gonçalves, L. Uwer, J.C. Eymard, T. Petit, M.A. Mouret-Reynier, E. Chamorey, G. Simon, M. Saghatchian, C. Cailliot, C. Le Tourneau
Publikováno v:
Breast, Vol 49, Iss , Pp 17-24 (2020)
Purpose: The Time to First Metastatic Recurrence (TFMR) could be considered as an indirect reflection of the tumour growth kinetics which plays an important role in cancer. Molecular subtypes such as expression of estrogen receptor are known predicti
Externí odkaz:
https://doaj.org/article/63f725b0531d40f6956dca8aa1ee3bd0
Autor:
E. Brain, A. Gonçalves, C. Cailliot, Agnes Loeb, Christine Levy, I Piot, Laurence Vanlemmens, C. Lefeuvre-Plesse, M. Campone, Florence Dalenc, Anne Jaffre, Mahasti Saghatchian, Amal Ghouadni, Barbara Pistilli, S Gourgou, Matthieu Carton, David Pérol, Francesco Ricci, M. Robain, Véronique Diéras
Publikováno v:
Cancer Research. 78:P5-20
Background: The management of HER2+ BC has changed dramatically with the introduction and widespread use of HER2-targeted therapies, especially in the adjuvant setting. However, there is relatively limited real-world information on the impact of adju
Autor:
A. Gonçalves, Bernard Asselain, Laurence Vanlemmens, G. Chenuc, T. Guesmia, Veronique Lorgis, Marc Debled, Thomas Bachelot, M. Robain, M.-A. Mouret-Reynier, D. Perol, Etienne Brain, Suzette Delaloge, L. Uwer, M. Campone, Florence Dalenc, C. Cailliot, P. Kerbrat, Véronique Diéras, Thierry Petit, Corinne Veyret, Christelle Jouannaud, William Jacot, J-M Ferrero, C. Courtinard, Christine Levy
Publikováno v:
Annals of Oncology
Annals of Oncology, 2016, 27 (9), pp.1725-1732. ⟨10.1093/annonc/mdw260⟩
Annals of Oncology, Oxford University Press (OUP), 2016, 27 (9), pp.1725-1732. ⟨10.1093/annonc/mdw260⟩
Annals of Oncology, Elsevier, 2016, 27 (9), pp.1725-1732. ⟨10.1093/annonc/mdw260⟩
Annals of Oncology, 2016, 27 (9), pp.1725-1732. ⟨10.1093/annonc/mdw260⟩
Annals of Oncology, Oxford University Press (OUP), 2016, 27 (9), pp.1725-1732. ⟨10.1093/annonc/mdw260⟩
Annals of Oncology, Elsevier, 2016, 27 (9), pp.1725-1732. ⟨10.1093/annonc/mdw260⟩
Background Bevacizumab combined with paclitaxel as first-line chemotherapy for patients with HER2-negative metastatic breast cancer (MBC) has led to mixed results in randomized trials, with an improvement in progression-free survival (PFS) but no sta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0bcaa6933153d824716b0b2e51ee0a6
https://hal.science/hal-02262350
https://hal.science/hal-02262350
Autor:
Gaëtane Simon, E. Jacquet, C. Cailliot, F. Divanon, Laurence Vanlemmens, Marc Debled, M. Breton, A. Gonçalves, Paul-Henri Cottu, Suzette Delaloge, C. Laurent, Thomas Bachelot, Thierry Petit, M. Leheurteur, M-A Mouret-Reynier, Bruno Coudert, Audrey Lardy-Cleaud, Emmanuel Chamorey, Barbara Pistilli, L. Campion
Publikováno v:
Annals of Oncology. 28:v92-v93
Publikováno v:
Annals of Oncology. 28:436-437
Autor:
F. Chomy, Benjamin Besse, F. Beghdad, Nicolas Girard, Christos Chouaid, C. Cailliot, Gaëtane Simon, Didier Debieuvre, Roland Schott, Radj Gervais, Bruno Coudert, X. Durando, Mathieu Robain, A. Madroszyk, Maurice Pérol
Publikováno v:
Revue des Maladies Respiratoires. 35:A106
Introduction Les donnees en vie reelle apportent des informations complementaires aux essais cliniques et contribuent a l’amelioration des connaissances scientifiques. Les etablissements de sante (EDS) (CLSS, CHU, CH et etablissements prives) geren
Autor:
J.-M. Miclea, Patrice Viens, J. Geneve, S. Provent, Catherine Lhommé, F. Viret, Joseph Gligorov, G. Lefevre, Jean-Pierre Lotz, B. Gosse, Vincent Ribrag, C. Cailliot, A. Goetschel, François Lokiec, Frédéric Selle, C. Dosquet, Michel Fabbro, Patricia Pautier
Publikováno v:
Bone Marrow Transplantation. 37:669-675
Topotecan has demonstrated activity in ovarian carcinomas. In order to increase the tumour response rate and to define the maximum tolerated dose (MTD) of topotecan, we decided to develop a high-dose phase I regimen supported by stem cell support. Hi
Autor:
G, Vassal, L, Borella, A, Pierre, R, Pamphile, B, Bourrie, K, Meflah, F, Amalric, I, Pauporte, J-L, Caillot, P, Formstecher, B, Demers, C, Dumontet, M, Grégoire, F, Lethiec, A-M, Boue, D, Tonelli, R, Pilsudski, L, Van Hijfte, C, Cailliot, P, Vrignaud, J-L, Merlin, P, Oudet, P-Y, Arnoux, C, Lassale
Publikováno v:
Bulletin du cancer. 94(12)
The French Cancer Plan 2003-2007 has made translational research central to its research programme, to ensure the care-research continuum and the quickest application possible for the most recent discoveries, for the patients' benefit. This is a new
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.